Search for scientific backing on Holistapet CBD cat treats and most articles quote the same handful of dog studies, then quietly assume the results transfer over to cats. They often don’t. Feline pharmacology differs enough from canine pharmacology that conclusions drawn from one species can’t be applied directly to the other.
What the Cornell Dog Study Actually Found
A frequently cited study out of Cornell University’s College of Veterinary Medicine looked at CBD’s effect on dogs with osteoarthritis. Researchers found that CBD oil reduced pain and increased comfort in the majority of dogs studied, with owners and veterinarians noting improved mobility over the trial period.
That result gets repeated constantly in pet CBD marketing. What gets left out: the study was conducted on dogs. It says nothing directly about cats, whose liver enzymes metabolize drugs and plant compounds through different pathways than a dog’s does. Citing it as evidence for cat products is a stretch, even if the underlying compound is the same.
Why Cats Are Different
Cats lack certain glucuronosyltransferase enzymes that dogs and humans use to break down many drugs and plant compounds, which is why cats process some medications far more slowly (acetaminophen toxicity in cats is the textbook example of this difference, though CBD and acetaminophen work through entirely separate mechanisms). Slower metabolism doesn’t necessarily mean CBD is dangerous for cats. It does mean dosing guidance borrowed from dog studies isn’t automatically safe to apply.
Peer-reviewed, cat-specific pharmacokinetic studies exist, but they remain limited in number compared to the dog literature. The available research generally looks at absorption and elimination rates rather than long-term therapeutic outcomes, meaning there’s more known about how CBD moves through a cat’s body than about whether it reliably treats any particular condition in cats.
The Endocannabinoid System in Brief
Every mammal, cats included, has an endocannabinoid system: a network of receptors (mainly CB1 and CB2) involved in regulating pain, inflammation, mood, and appetite. CBD interacts with this system, though not by binding directly to CB1 and CB2 receptors the way THC does. Instead it appears to influence how the body processes its own naturally occurring cannabinoids.
This is legitimate biology, not marketing fiction. The gap is between “CBD interacts with a real physiological system” and “CBD treats condition X in cats,” a much bigger claim that current evidence doesn’t fully support.
What Veterinarians Say
The American Veterinary Medical Association maintains a resource on cannabis use in pets and has been cautious about drug-like claims for CBD products, largely because none of them carry FDA approval as animal drugs. That caution isn’t the same as a blanket warning against use. It reflects the reality that:
- No CBD product is currently FDA-approved for any condition in cats or dogs
- Manufacturers can’t legally make specific therapeutic claims (treating anxiety, arthritis, seizures) without that approval
- Veterinarians in some states face restrictions on formally recommending cannabis-derived products, even informally
- Anecdotal reports from pet owners are common, but anecdote isn’t the same as controlled data
Most veterinary guidance lands on a similar note: if a cat owner is going to try a hemp product, doing so under veterinary supervision, starting at a low dose, and monitoring closely, matters more than which brand gets picked.
Final Thoughts
The science on CBD in cats is real but young, and the dog research doesn’t fill that gap the way marketing often implies. Treating CBD cat treats as a supplement worth monitoring, rather than a proven remedy, matches where the evidence currently stands.
